Business Context and Reporting Period
Company: Oramed Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 30, 2025
Event: Completion of the second and final tranche of a warrant repurchase agreement with Scilex Holding Company.
Key Financial Metrics
This filing reports a specific transaction rather than comprehensive financial statements. Key transaction metrics include:
- Total Proceeds Received: $28,500,000 (aggregate payments from Scilex).
- Second Tranche Payment: $14,000,000 (inclusive of prepayments).
- Second Tranche Option Fee: $750,000.
- Warrants Repurchased (Tranche 2): 3,370,000 warrants to purchase Scilex Common Stock.
- Warrants Repurchased (Total): 6,500,000 warrants (3,130,000 in Tranche 1; 3,370,000 in Tranche 2).
- Exercise Price of Repurchased Warrants: $0.01 per share.
Note: The filing text does not provide clear values for revenue, net profit, operating cash flow, margins, debt levels, or general liquidity metrics beyond the specific transaction proceeds.
Material Changes Versus Prior Period
The filing details the completion of a previously disclosed agreement:
- July 22, 2025: Oramed entered into an Option Agreement with Scilex to repurchase 6,500,000 warrants for an aggregate price of $27,000,000 plus option fees.
- September 30, 2025: First tranche completed; Scilex repurchased 3,130,000 warrants for $13,000,000 plus a $750,000 option fee.
- December 30, 2025: Second tranche completed; Scilex repurchased the remaining 3,370,000 warrants for $14,000,000 plus a $750,000 option fee.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the successful execution of the warrant repurchase agreement as previously disclosed. No forward-looking guidance, strategic outlook, or specific risk factors are detailed in this specific 8-K text beyond the transaction mechanics.
Unusual Items: The receipt of $28.5 million in aggregate payments represents a significant non-operating cash inflow related to the divestiture of warrant assets held by the Company.
Investor Verification Checklist
- Verify the classification of the $28.5 million proceeds in the upcoming financial statements (e.g., gain on sale of assets vs. other income).
- Confirm the impact of this cash inflow on the Company's current liquidity position and cash runway.
- Review the original July 2025 Option Agreement to ensure all conditions for the final tranche were met.
- Assess whether the repurchase of Scilex warrants alters any existing strategic partnership or royalty arrangements between Oramed and Scilex.